Shigella Sonnei 53G Human Infection Study in Kenyan Adults

NCT05959616 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Shigellosis

Interventions

BIOLOGICAL: Shigella sonnei 53G
DRUG: Ciprofloxacin 500 mg

Sponsor

University of Oxford

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]